Physician profile
Mary Taylor
NPI 1740201243
$6,202.24
in general payments reported to CMS, 2019-2025
42 companies · $873 in 2025
The $873 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $394 · 2021: $490 · 2022: $1,214 · 2023: $1,345 · 2024: $1,175 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,392.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $918.88 | 2019-2025 | |
| Ucb, INC. | $800.17 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Avanir Pharmaceuticals, INC. | $412.70 | 2020-2022 | |
| Pfizer INC. | $401.86 | 2019-2024 | |
| Emd Serono, INC. | $398.52 | 2019-2024 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $325.30 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $303.64 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $279.73 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Otsuka America Pharmaceutical, INC. | $218.30 | 2023-2024 | Nuedexta, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $214.72 | 2022 | |
| Abbvie INC. | $195.56 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $167.38 | 2019-2024 | Emgality, Amyvid |
| Genentech USA, INC. | $158.82 | 2019-2024 | Ocrevus, Enspryng |
| Eisai INC. | $130.01 | 2022-2024 | |
| Genzyme Corporation | $122.96 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.